The company stated that two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company’s oncology portfolio.
https://www.pharmalive.com/wp-content/uploads/2022/05/ReutersAstraZeneca5-27-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-27 03:52:112022-06-27 09:31:48AstraZeneca gets EU backing for targeted breast cancer therapies
